



Sesen Bio to Present Regulatory and Business Development Update at the Canaccord Genuity 40th Annual Growth Conference

August 5, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 5, 2020-- **August 5, 2020 – Sesen Bio** (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020. The Company will provide an update on the regulatory process in the US and Europe, and the BD process outside the US.

Event: Canaccord Genuity 40th Annual Growth Conference

Date: August 13, 2020

Time: 11:00-11:25 AM ET

A live webcast of the Company's presentation will be accessible from the Investors & Media section of Sesen Bio's website, www.sesenbio.com. An archived replay of the webcast will be available on the Company's website for 90 days after the conference.

About Sesen Bio

Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is currently in a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2019, the Company initiated the BLA submission for Vicineum to the FDA under Rolling Review. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China, for which the Company has partnered with Qilu Pharmaceutical for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC. For more information, please visit the company's website at www.sesenbio.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200805005909/en/): <https://www.businesswire.com/news/home/20200805005909/en/>

Erin Clark, Vice President, Corporate Strategy & Investor Relations
ir@sesenbio.com

Source: Sesen Bio, Inc.